The European Haemophilia Consortium on Innovation and Patient Access

Key Takeaways

• EHC represents patient groups from 49 European countries.
• Advocates equitable access to both basic prophylaxis and advanced therapies.
• Provides HTA training so patients can influence reimbursement decisions.
• Focuses on underserved women, ultra‑rare disorders, and aging patients.
• Pushes transparent, multi‑stakeholder collaborations to sustain innovation across Europe.

Pulse Analysis

The European Haemophilia Consortium (EHC) has become a pivotal voice for over 400,000 people worldwide living with haemophilia and related bleeding disorders. By uniting national patient organisations across 49 countries, EHC amplifies grassroots concerns in policy forums, regulatory reviews, and health‑technology assessments. This broad representation enables the consortium to highlight stark inequities—some health systems provide cutting‑edge gene therapies, while others struggle to deliver basic prophylaxis—driving targeted advocacy that seeks uniform standards of care across the continent.

EHC’s multi‑pronged approach blends education, capacity‑building, and strategic partnerships. Training programmes equip patient representatives to speak confidently during HTA deliberations, ensuring reimbursement decisions reflect real‑world needs. Simultaneously, the consortium runs awareness campaigns for historically overlooked groups, such as women with von Willebrand disease and families affected by ultra‑rare factor deficiencies. By fostering collaborations with the World Federation of Hemophilia, European rare‑disease alliances, and industry partners, EHC creates a transparent ecosystem where data sharing, long‑term safety monitoring, and sustainable pricing models can thrive.

Looking ahead, EHC prioritises shared decision‑making, holistic care, and the inclusion of under‑represented populations in clinical research. Initiatives like the Extremely Rare Inhibitor Network summit connect isolated families, while dedicated women’s‑health summits aim to close diagnostic gaps. The consortium’s call for transparent, equitable partnerships signals a broader shift: innovation alone is insufficient without mechanisms that guarantee access for every patient, regardless of national wealth or healthcare infrastructure. This balanced focus on breakthrough therapies and systemic equity positions EHC as a catalyst for lasting change in Europe’s rare‑disease landscape.